Skip to content

Study · Animal study (in vivo) · rat · 2009

3 results

Audiogenic epilepsy in mice with different genotypes after neonatal treatments enhancing neurogenesis in dentate gyrus.

Timoshenko TV, Perepelkina OV, Markina NV, Revischin AV, Pavlova GV, Poletaeva II, Sukhih GT

Bulletin of experimental biology and medicine1 Apr 2009

PMID19704948 (opens in a new tab)DOI10.1007/s10517-009-0558-3 (opens in a new tab)PepBankPUB-19704948
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Wistar and KM rats, neonatal semax or L-NAME altered the audiogenic seizure pattern at 1 month of age in both strains.

    In plain wordsIn rats, early-life treatment with Semax or L-NAME changed the pattern of sound-triggered seizures in both strains.

    Peptide
    Semax
    Outcome
    Direction not reportedAudiogenic seizure pattern at 1 month
    Study

    ratn: not reported in source

    Wistar and KM rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 mg/kg · days 7-11 of lifeAs given in this study (rat).

    Source sentences

    Summary
    Alterations of audiogenic seizures pattern were revealed in rats of both strains at the age of 1 month, while changes in seizure severity were genotype-dependent.
    1 context sentence
    Summary · context
    Pups of Wistar and KM rats (with predisposition to audiogenic epilepsy) were daily injected with neuropeptide semax (50 mg/kg) or NO-synthase inhibitor L-NAME (50 mg/kg) on days 7-11 of life.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Wistar and KM rats, changes in seizure severity after semax and L-NAME were genotype-dependent and differently directed.

    In plain wordsIn rats, Semax and L-NAME changed seizure severity in different directions depending on the rat strain.

    Peptide
    Semax
    Outcome
    MixedSeizure severity by genotype
    Study

    ratn: not reported in source

    Wistar and KM rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 mg/kg · days 7-11 of lifeAs given in this study (rat).

    Source sentences

    Summary
    Alterations of audiogenic seizures pattern were revealed in rats of both strains at the age of 1 month, while changes in seizure severity were genotype-dependent.
    2 context sentences
    Summary · context
    Genotype-dependent alterations of seizure severity after administration of semax and L-NAME were differently directed.
    Summary · context
    Pups of Wistar and KM rats (with predisposition to audiogenic epilepsy) were daily injected with neuropeptide semax (50 mg/kg) or NO-synthase inhibitor L-NAME (50 mg/kg) on days 7-11 of life.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, semax and L-NAME enhanced neurogenesis in the dentate gyrus of the hippocampus.

    In plain wordsIn rats, Semax and L-NAME increased the making of new nerve cells in a hippocampal region.

    Peptide
    Semax
    Outcome
    IncreaseNeurogenesis in dentate gyrus
    Study

    ratn: not reported in source

    Wistar and KM rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    50 mg/kg · days 7-11 of lifeAs given in this study (rat).

    Source sentences

    Summary
    Both agents enhance neurogenesis in the dentate gyrus of the hippocampus
    1 context sentence
    Summary · context
    Pups of Wistar and KM rats (with predisposition to audiogenic epilepsy) were daily injected with neuropeptide semax (50 mg/kg) or NO-synthase inhibitor L-NAME (50 mg/kg) on days 7-11 of life.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.